

Amendments to the Specification:

Please replace the 1st paragraph of page 1 with the following rewritten paragraphs:

Reference to Related Applications

This is a divisional of ~~co-pending applications~~ ~~Serial number~~ U.S.S.N. 08/400,796 filed on March 7, 1995, now U.S. Pat. No. 5,874,531.

Amendments to the Specification:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-2. (Cancelled)

3. (Currently amended) A pharmaceutical preparation for tolerizing, comprising a pharmaceutically acceptable carrier and

an amount of an isolated human polypeptide effective for tolerizing an individual to an autoantigen, said human polypeptide consisting of a sequence motif for an HLA-DR protein containing the core MHC binding residues, wherein said HLA-DR protein is selected from the group consisting of HLA-DR2 and HLA-DR4 ~~consisting essentially of an amino acid sequence corresponding to the core MHC binding residues of a sequence motif for an HLA-DR protein;~~

wherein said sequence motif for said HLA-DR protein is based upon the structure of the HLA-DR peptide binding site;

wherein said HLA-DR protein is associated with a human autoimmune disease selected from Pemphigus Vulgaris (PV) and Multiple Sclerosis (MS);

wherein said polypeptide binds to said HLA-DR protein;

wherein said polypeptide bound to said HLA-DR protein activates autoreactive T cells from a subject having said autoimmune disease; and

wherein said protein is a ~~non-collagen and~~ non-myelin basic protein polypeptide.

4. (Original) The pharmaceutical preparation of claim 3 wherein said HLA-DR protein is an HLA-DR4 protein and said autoimmune disease is pemphigus vulgaris.

5. (Original) The pharmaceutical preparation of claim 4 wherein said motif is PV motif #1.

6. (Currently amended) The pharmaceutical preparation of claim 4, wherein said ~~amino acid sequence~~ polypeptide consists ~~essentially~~ of an amino acid sequence selected from ~~the group consisting of~~ SEQ ID NO.: 1, SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, ~~and or~~ SEQ ID NO.: 7.

7-10. **(Cancelled)**

11. **(Original)** A method of tolerizing an individual to an autoantigen of pemphigus vulgaris comprising administering an effective amount of the pharmaceutical preparation of any one of claims 4-6 to a subject in need of such treatment.

12. **(Cancelled)**

13. **(Currently amended)** A pharmaceutical preparation for vaccinating an individual at risk of an autoimmune disease, comprising a pharmaceutically acceptable carrier and an amount of an immunogenic ~~preparation~~ antigen from a human pathogen, and effective to immunize against the a human pathogen, wherein said antigen does not comprise a sequence motif for an HLA-DR protein containing the core MHC binding residues, wherein said HLA-DR protein is selected from the group consisting of HLA-DR2 and HLA-DR4 that in its native form includes a polypeptide having an amino acid sequence corresponding to the core MHC binding residues of a sequence motif for an HLA-DR protein; wherein said sequence motif for said HLA-DR protein is based upon the structure of the HLA-DR peptide binding site; wherein said HLA-DR protein is associated with a human autoimmune disease selected from Pemphigus Vulgaris (PV) and Multiple Sclerosis (MS); wherein said polypeptide binds to said HLA-DR protein; and wherein said polypeptide bound to said HLA-DR protein activates autoreactive T cells from a subject having said autoimmune disease; ~~and~~ ~~wherein said preparation is free of a polypeptide corresponding to said sequence.~~

14. **(Original)** The pharmaceutical preparation of claim 13 wherein said HLA-DR protein is an HLA-DR4 protein and said autoimmune disease is pemphigus vulgaris.

15. **(Original)** The pharmaceutical preparation of claim 14 wherein said motif is PV motif #1.

16. **(Currently Amended)** The pharmaceutical preparation of claim 14 wherein said ~~amino acid-sequence~~ polypeptide consists ~~essentially~~ of an amino acid sequence selected from ~~the group consisting of~~ SEQ ID NO.: 1, SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, ~~and~~ or SEQ ID NO.: 7.

17-29. **(Cancelled)**